PROMISE Study Research Grant

Full Name: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness (PROMISE)

Focus Areas:

• Prostate cancer research
• Germline genetic mutations (inherited genes) in prostate cancer
• Understanding critical role of genetics in disease progression and treatment
• Clinical trial matching and improved treatment options
• Patient outcomes and survival

Funded Recipients/Collaborators:

• UW Medicine: Collaborative research on germline genetic mutations; long-term study on prostate cancer causes, prevention strategies, diagnostics, and survival. UW has identified/assembled up to 80% of genes expressed in prostate cancer, developed one of largest serum and tissue banks, advanced studies of bone biology and skeletal metastases, assembled information on 300+ hereditary prostate cancer families.
• Johns Hopkins Medicine: Prostate Cancer Program research crossing multiple specialties; studying detection, diagnosis, treatment approaches, genetic underpinnings, DNA methylation, inflammation's role in disease, and development of biomarkers to improve detection and guide personalized treatment.
• Prostate Cancer Clinical Trials Consortium (PCCTC): Led by internationally recognized leaders; designs, implements, and completes early-phase clinical trials translating discoveries to improved standards of care. Manages efficient trial selection, reporting, site management, clinical operations, and data analysis for PROMISE study.

Research Goals:

• Improve knowledge of germline genetic mutations in prostate cancer
• Identify genetic risk factors
• Develop biomarkers for detection, diagnosis, risk evaluation, and disease monitoring
• Reduce overtreatment and quality-of-life impacts
• Improve clinical trial matching and treatment options